231 related articles for article (PubMed ID: 17404291)
1. IL-28 elicits antitumor responses against murine fibrosarcoma.
Numasaki M; Tagawa M; Iwata F; Suzuki T; Nakamura A; Okada M; Iwakura Y; Aiba S; Yamaya M
J Immunol; 2007 Apr; 178(8):5086-98. PubMed ID: 17404291
[TBL] [Abstract][Full Text] [Related]
2. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs.
Rosenthal FM; Cronin K; Bannerji R; Golde DW; Gansbacher B
Blood; 1994 Mar; 83(5):1289-98. PubMed ID: 8118032
[TBL] [Abstract][Full Text] [Related]
4. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells.
Zou JP; Yamamoto N; Fujii T; Takenaka H; Kobayashi M; Herrmann SH; Wolf SF; Fujiwara H; Hamaoka T
Int Immunol; 1995 Jul; 7(7):1135-45. PubMed ID: 8527411
[TBL] [Abstract][Full Text] [Related]
5. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
6. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.
Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K
J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225
[TBL] [Abstract][Full Text] [Related]
7. Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.
Kaiga T; Sato M; Kaneda H; Iwakura Y; Takayama T; Tahara H
J Immunol; 2007 Jun; 178(12):7571-80. PubMed ID: 17548592
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
Hafner M; Falk W; Echtenacher B; Männel DN
Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumor activity of interleukin 21 mediated by natural killer cells.
Wang G; Tschoi M; Spolski R; Lou Y; Ozaki K; Feng C; Kim G; Leonard WJ; Hwu P
Cancer Res; 2003 Dec; 63(24):9016-22. PubMed ID: 14695220
[TBL] [Abstract][Full Text] [Related]
10. Local secretion of IFN-gamma induces an antitumor response: comparison between T cells plus IL-2 and IFN-gamma transfected tumor cells.
Sadanaga N; Nagoshi M; Lederer JA; Joo HG; Eberlein TJ; Goedegebuure PS
J Immunother; 1999 Jul; 22(4):315-23. PubMed ID: 10404433
[TBL] [Abstract][Full Text] [Related]
11. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
Aruga A; Aruga E; Cameron MJ; Chang AE
J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 12 gene transfer into skin distant from the tumor site elicits antimetastatic effects equivalent to local gene transfer.
Oshikawa K; Rakhmilevich AL; Shi F; Sondel PM; Yang N; Mahvi DM
Hum Gene Ther; 2001 Jan; 12(2):149-60. PubMed ID: 11177552
[TBL] [Abstract][Full Text] [Related]
13. Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
Shiloni E; Karp SE; Custer MC; Shilyansky J; Restifo NP; Rosenberg SA; Mulé JJ
Cancer Immunol Immunother; 1993 Oct; 37(5):286-92. PubMed ID: 8402732
[TBL] [Abstract][Full Text] [Related]
14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma-inducing factor elicits antitumor immunity in association with interferon-gamma production.
Tan J; Crucian BE; Chang AE; Aruga E; Aruga A; Dovhey SE; Tanigawa K; Yu H
J Immunother; 1998 Jan; 21(1):48-55. PubMed ID: 9456436
[TBL] [Abstract][Full Text] [Related]
16. Induction of antitumor immunity by direct intratumoral injection of a recombinant adenovirus vector expressing interleukin-12.
Gambotto A; Tüting T; McVey DL; Kovesdi I; Tahara H; Lotze MT; Robbins PD
Cancer Gene Ther; 1999; 6(1):45-53. PubMed ID: 10078963
[TBL] [Abstract][Full Text] [Related]
17. Regression of engineered myeloma cells secreting interferon-gamma-inducing factor is mediated by both CD4(+)/CD8(+) T and natural killer cells.
Xiang J; Chen Z; Huang H; Moyana T
Leuk Res; 2001 Oct; 25(10):909-15. PubMed ID: 11532525
[TBL] [Abstract][Full Text] [Related]
18. Repeated restraint stress impairs the antitumor T cell response through its suppressive effect on Th1-type CD4+ T cells.
Li T; Harada M; Tamada K; Abe K; Nomoto K
Anticancer Res; 1997; 17(6D):4259-68. PubMed ID: 9494518
[TBL] [Abstract][Full Text] [Related]
19. IL-7 inhibits tumor growth by promoting T cell-mediated antitumor immunity in Meth A model.
Tang JC; Shen GB; Wang SM; Wan YS; Wei YQ
Immunol Lett; 2014; 158(1-2):159-66. PubMed ID: 24406503
[TBL] [Abstract][Full Text] [Related]
20. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
